Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2026)

Amylyx Pharmaceuticals' Assets Average history runs 5 years deep, the most recent figure standing at $313.1 million for Q1 2026.

• In Q1 2026, Assets Average rose 51.52% year-over-year to $313.1 million; the TTM figure through Mar 2026 stood at $313.1 million (up 51.52% YoY), while the FY2025 annual figure was $263.1 million, down 25.99% from the prior year.
• Assets Average was $313.1 million for Q1 2026 at Amylyx Pharmaceuticals, down from $347.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $492.0 million in Q4 2023 to a low of $190.0 million in Q1 2022.
• Historically, Assets Average has averaged $318.9 million across 5 years, with a median of $291.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Assets Average jumped 126.26% in 2023, then slumped 55.79% in 2025.
• A 5-year view of Assets Average shows it stood at $286.4 million in 2022, then surged by 71.77% to $492.0 million in 2023, then slumped by 54.84% to $222.2 million in 2024, then jumped by 56.5% to $347.7 million in 2025, then decreased by 9.94% to $313.1 million in 2026.
• The last three Assets Average figures came in at $313.1 million (Q1 2026), $347.7 million (Q4 2025), and $278.7 million (Q3 2025), per Business Quant data.